Kevzara set to be reimbursed for certain RA patients in England

The UK’s HTA body NICE has published draft guidance recommending Kevzara (sarilumab) for certain patients with rheumatoid arthritis.

The National Institute for Health and Care Excellence recommends Kevzara in combination with the disease-modifying anti-rheumatic drug (DMARD) methotrexate as a second-line option for severe active RA patients.

It’s also recommended as a monotherapy in the second-line, for certain patients who have not responded well to treatments and cannot take the biologic rituximab.

If confirmed as final guidance in November 2017, reimbursement will be provided for the drug’s routine use in England, for these indications.

Sanofi has agreed to a patient access scheme as a condition of the recommendation.